A higher proportion of participants with type 2 diabetes mellitus treated with canagliflozin reported interest in continuing treatment upon study completion compared with participants who received other treatments (placebo or sitagliptin).

Participants treated with canagliflozin were also more likely to be satisfied with their weight and physical and emotional health, demonstrating improved health-related quality of life compared with placebo or sitagliptin.

Further research is needed to determine if these positive outcomes will lead to improved disease management behaviors and treatment adherence among people with type 2 diabetes mellitus receiving canagliflozin.